Astrazeneca Plc ADR (AZN)

$193.03 +5.87 (3.14%)
Market Cap 290.72B
Revenue (ttm) 54.07B
Net Income (ttm) 7.04B
EPS (ttm) N/A
PE Ratio 20.17
Forward PE 17.99
Profit Margin 13.01%
Debt to Equity Ratio 0.67
Volume 3,116,567
Avg Vol 6,638,534
Day's Range N/A - N/A
Shares Out 1.55B
Stochastic %K 94%
Beta 0.34
Analysts Strong Sell
Price Target $204.33

Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze,...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 44 20 3749 5000
Address:
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom
truehealthvalue
truehealthvalue Jun. 5 at 9:27 AM
$AZN I would look at $ELTX, About to take off, it will be worth billions in a short time
0 · Reply
P0rNsTaR
P0rNsTaR Jun. 3 at 7:07 PM
$ABVX with MC at under $6B, there's a almost 300% upside here. $LLY $AZN
0 · Reply
monstertrades1
monstertrades1 Jun. 3 at 7:02 PM
$AREC $AZN $BMEA $MTVA $WMT
0 · Reply
G101SPM
G101SPM Jun. 3 at 6:52 PM
#SHOWTIME American Diabetes Association Scientific Conference (June 4-8) Scheduled to appear: $AREC, $AZN, $BMEA, $MTVA, IPSC... Walmart Inc. Annual General Meeting (June 4) Scheduled to appear: $WMT
0 · Reply
Chipwars
Chipwars Jun. 3 at 5:23 PM
$AZN Only 16x PE. Good entry point here, IMO. Astrazeneca. https://finance.yahoo.com/sectors/healthcare/articles/astrazenecas-expanding-cancer-portfolio-sustain-140900834.html
0 · Reply
Chipwars
Chipwars Jun. 3 at 10:52 AM
$AZN Astrazeneca. Deutsche Bank are crooked short sellers. They've done this before. The stock will come back as they are proved wrong. Again.
0 · Reply
Chipwars
Chipwars Jun. 3 at 10:25 AM
$AZN https://www.fiercepharma.com/pharma/asco-astrazenecas-imfinzi-imjudo-duo-shines-earlier-stage-liver-cancer-win
0 · Reply
GreenEnergy7B
GreenEnergy7B Jun. 3 at 9:33 AM
$ALT "Weight-loss drugs can cut breast cancer risk by up to 30%, studies suggest" "The first study, a retrospective analysis of 110,000 women aged between 45 and 80, found those who took GLP-1 medications were 30% less likely to develop breast cancer than those who did not." https://www.theguardian.com/science/2026/jun/02/weight-loss-drugs-cut-cancer-risk-studies $NVO $PFE $AZN $SNY
0 · Reply
DeadInvestor
DeadInvestor Jun. 2 at 6:23 PM
$TVTX BofA raised their target to $59 from $50 on May 28, following the patent extension news. H.C. Wainwright raised its price target on the stock to $67 from $57 $AZN $NVS better buy TVTX fast, as The price will continue to climb, ratcheting up the buyout price for acquirer.
0 · Reply
Chipwars
Chipwars Jun. 2 at 2:08 PM
$AZN Astrazeneca gives hope to thousands of people : https://www.stocktitan.net/news/AZN/camizestrant-combination-delayed-time-to-first-progression-by-55-and-3aod76a3qnbk.html
0 · Reply
Latest News on AZN
NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History

Fri, 05 Jun 2026 08:55:00 -0400 - 3 hours ago

NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History

AstraZeneca PLC (AZN) Shares Surge 3.1% -- What GF Score of 83 Tells Investors

2026-06-04T22:12:43.000Z - 17 hours ago

AstraZeneca PLC (AZN) Shares Surge 3.1% -- What GF Score of 83 Tells Investors

AstraZeneca (AZN) Engages with FDA Leadership on Rare Disease Initiatives

2026-06-04T19:26:27.000Z - 20 hours ago

AstraZeneca (AZN) Engages with FDA Leadership on Rare Disease Initiatives

FTSE 100 drops amid China banking concerns and falling oil prices

Thu, 04 Jun 2026 08:57:19 -0400 - 1 day ago

FTSE 100 drops amid China banking concerns and falling oil prices

AstraZeneca CEO: AI is affecting every part of our company

2026-06-03T19:55:51.000Z - 1 day ago

AstraZeneca CEO: AI is affecting every part of our company

AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment For Ampligen In Pancreatic Cancer; Stock Down

2026-06-03T14:39:51.000Z - 2 days ago

AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment For Ampligen In Pancreatic Cancer; Stock Down

AstraZeneca (AZN) Benefits from New FDA Guidance on Gene Therapy Development

2026-06-02T15:34:19.000Z - 3 days ago

AstraZeneca (AZN) Benefits from New FDA Guidance on Gene Therapy Development

AstraZeneca's Camizestrant Shows Strong Results in Phase III Trial (AZN)

2026-06-02T14:58:13.000Z - 3 days ago

AstraZeneca's Camizestrant Shows Strong Results in Phase III Trial (AZN)

AstraZeneca (AZN) Reports Promising Phase III Trial Results for Camizestrant

2026-06-02T14:54:04.000Z - 3 days ago

AstraZeneca (AZN) Reports Promising Phase III Trial Results for Camizestrant

AstraZeneca announces additional results from Phase III Serena-6 trial

2026-06-02T13:35:12.000Z - 3 days ago

AstraZeneca announces additional results from Phase III Serena-6 trial

AstraZeneca reports ‘further positive results’ from Phase 3 SERENA-6 trial

2026-06-02T13:19:29.000Z - 3 days ago

AstraZeneca reports ‘further positive results’ from Phase 3 SERENA-6 trial

Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial

Tue, 02 Jun 2026 08:00:00 -0400 - 3 days ago

Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial

AstraZeneca PLC (AZN) Stock Down 3.2% but Still Overvalued -- GF Score: 84/100

2026-06-01T22:11:53.000Z - 3 days ago

AstraZeneca PLC (AZN) Stock Down 3.2% but Still Overvalued -- GF Score: 84/100

5 Foreign Stocks That Could Beat The S&P 500

Mon, 01 Jun 2026 14:44:40 -0400 - 3 days ago

5 Foreign Stocks That Could Beat The S&P 500

AstraZeneca (AZN) Reports Positive Results in Phase III Trial for HCC Treatment

2026-06-01T14:34:28.000Z - 4 days ago

AstraZeneca (AZN) Reports Positive Results in Phase III Trial for HCC Treatment

AstraZeneca announces reuslts from EMERALD-3 Phase III trial of Imfinzi

2026-06-01T12:42:58.000Z - 4 days ago

AstraZeneca announces reuslts from EMERALD-3 Phase III trial of Imfinzi

AstraZeneca Scores In Liver Cancer On Its Path To $40 Billion In Oncology Sales

2026-06-01T12:00:19.000Z - 4 days ago

AstraZeneca Scores In Liver Cancer On Its Path To $40 Billion In Oncology Sales

IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial

Mon, 01 Jun 2026 08:00:00 -0400 - 4 days ago

IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial

AstraZeneca Transcript: Investor update

Jun 1, 2026, 8:00 AM EDT - 4 days ago

AstraZeneca Transcript: Investor update

AstraZeneca Slides: Investor update

Jun 1, 2026, 8:00 AM EDT - 4 days ago

AstraZeneca Slides: Investor update

BioInvent to Host a KOL Event in Stockholm on June 11, 2026, to Discuss Updated BI-1206 & BI-1808 Data in Hematology

Mon, 01 Jun 2026 05:20:00 -0400 - 4 days ago

BioInvent to Host a KOL Event in Stockholm on June 11, 2026, to Discuss Updated BI-1206 & BI-1808 Data in Hematology

Weekly Buzz: AstraZeneca, JNJ Get FDA Nod; Eli Lilly To Acquire Curevo; APGE Advances Zumilokibart

2026-05-29T15:00:00.000Z - 7 days ago

Weekly Buzz: AstraZeneca, JNJ Get FDA Nod; Eli Lilly To Acquire Curevo; APGE Advances Zumilokibart

Anselamimab Shows Promise in Phase 3 Trials for AL Amyloidosis (AZN)

2026-05-29T14:36:14.000Z - 7 days ago

Anselamimab Shows Promise in Phase 3 Trials for AL Amyloidosis (AZN)

AstraZeneca says CARES Phase 3 clinical program did not meet primary endpoint

2026-05-29T13:09:01.000Z - 7 days ago

AstraZeneca says CARES Phase 3 clinical program did not meet primary endpoint

AstraZeneca (AZN) Gains Approval for Imfinzi in Bladder Cancer Treatment

2026-05-29T10:51:17.000Z - 7 days ago

AstraZeneca (AZN) Gains Approval for Imfinzi in Bladder Cancer Treatment

AstraZeneca Imfinzi combination approved in the U.S.

2026-05-29T09:30:13.000Z - 7 days ago

AstraZeneca Imfinzi combination approved in the U.S.

FDA Approves IMFINZI Combination With BCG For Non-muscle-invasive Bladder Cancer In Adults

2026-05-29T06:19:09.000Z - 7 days ago

FDA Approves IMFINZI Combination With BCG For Non-muscle-invasive Bladder Cancer In Adults

AstraZeneca’s durvalumab approved in U.S. for NMIBC patients

2026-05-29T02:45:10.000Z - 7 days ago

AstraZeneca’s durvalumab approved in U.S. for NMIBC patients

IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer

Thu, 28 May 2026 21:18:00 -0400 - 7 days ago

IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer

IMFINZI (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer

2026-05-29T01:18:00.000Z - 7 days ago

IMFINZI (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer

AstraZeneca (AZN) Receives FDA Approval for Imfinzi in Bladder Cancer Treatment

2026-05-28T23:56:35.000Z - 7 days ago

AstraZeneca (AZN) Receives FDA Approval for Imfinzi in Bladder Cancer Treatment

AstraZeneca (AZN) Gains FDA Approval for Imfinzi in Bladder Cancer Treatment

2026-05-28T19:40:01.000Z - 7 days ago

AstraZeneca (AZN) Gains FDA Approval for Imfinzi in Bladder Cancer Treatment

AstraZeneca (AZN) Secures U.S. Approval for Imfinzi Combination Therapy

2026-05-28T19:38:05.000Z - 7 days ago

AstraZeneca (AZN) Secures U.S. Approval for Imfinzi Combination Therapy

AstraZeneca confirms FDA approves Imfinzi combo for bladder cancer

2026-05-28T17:38:24.000Z - 7 days ago

AstraZeneca confirms FDA approves Imfinzi combo for bladder cancer

FDA approves durvalumab combo for high-risk non-muscle invasive bladder cancer

2026-05-28T17:26:34.000Z - 7 days ago

FDA approves durvalumab combo for high-risk non-muscle invasive bladder cancer

AZN's Patent Granted in Canada Strengthens Position in Male Infertility Treatment

2026-05-27T15:36:00.000Z - 9 days ago

AZN's Patent Granted in Canada Strengthens Position in Male Infertility Treatment

AstraZeneca (AZN) Receives FDA Extension for Drug Review

2026-05-27T12:50:33.000Z - 9 days ago

AstraZeneca (AZN) Receives FDA Extension for Drug Review

AstraZeneca says FDA extends PDUFA date to review camizestrant data for NDA

2026-05-27T11:39:25.000Z - 9 days ago

AstraZeneca says FDA extends PDUFA date to review camizestrant data for NDA

FDA Extends Review Of AstraZeneca's Camizestrant NDA In ESR1-Mutated Advanced Breast Cancer

2026-05-27T08:49:11.000Z - 9 days ago

FDA Extends Review Of AstraZeneca's Camizestrant NDA In ESR1-Mutated Advanced Breast Cancer

AstraZeneca: FDA Extends PDUFA Date Related To NDA For Camizestrant

2026-05-27T06:23:33.000Z - 9 days ago

AstraZeneca: FDA Extends PDUFA Date Related To NDA For Camizestrant

US FDA extends review of AstraZeneca's experimental breast cancer pill

Wed, 27 May 2026 02:23:17 -0400 - 9 days ago

US FDA extends review of AstraZeneca's experimental breast cancer pill

Top losers in morning trade: gujarat state petronet at ₹268.35 down 7.13%, techno electric at ₹1,121.80 slips 6.61%, astrazeneca at ₹8,383.00 falls 6.47%

2026-05-27T06:00:15.000Z - 9 days ago

Top losers in morning trade: gujarat state petronet at ₹268.35 down 7.13%, techno electric at ₹1,121.80 slips 6.61%, astrazeneca at ₹8,383.00 falls 6.47%

AstraZeneca PLC: US FDA decision date on camizestrant extended

2026-05-27T06:00:00.000Z - 9 days ago

AstraZeneca PLC: US FDA decision date on camizestrant extended

How Big Pharma Is Turning Industrial Heat Into A Strategic Asset

Tue, 26 May 2026 09:41:18 -0400 - 10 days ago

How Big Pharma Is Turning Industrial Heat Into A Strategic Asset

AstraZeneca Gets Positive CHMP Opinion For Camizestrant Combination In Breast Cancer

2026-05-26T07:18:00.000Z - 10 days ago

AstraZeneca Gets Positive CHMP Opinion For Camizestrant Combination In Breast Cancer

Emerging Hope in Multiple Myeloma Market: 7 Late-Stage Therapies Nearing the Finish Line | DelveInsight

2026-05-25T17:00:00.000Z - 10 days ago

Emerging Hope in Multiple Myeloma Market: 7 Late-Stage Therapies Nearing the Finish Line | DelveInsight

Insider Sell: Mani Sharma Sells Shares of AstraZeneca PLC

2026-05-23T01:31:38.000Z - 13 days ago

Insider Sell: Mani Sharma Sells Shares of AstraZeneca PLC

AstraZeneca (AZN) Engages With Key Opinion Leaders at ASCO 2023

2026-05-22T20:51:41.000Z - 13 days ago

AstraZeneca (AZN) Engages With Key Opinion Leaders at ASCO 2023

AstraZeneca to Present Key Clinical Findings at ASCO 2026

2026-05-22T16:51:05.000Z - 13 days ago

AstraZeneca to Present Key Clinical Findings at ASCO 2026

FDA Approves AstraZeneca And Daiichi's Datroway For Treating Metastatic Breast Cancer

2026-05-22T15:53:13.000Z - 14 days ago

FDA Approves AstraZeneca And Daiichi's Datroway For Treating Metastatic Breast Cancer

AstraZeneca (AZN) Gains U.S. Approval for Datroway in Breast Cancer Treatment

2026-05-22T15:27:26.000Z - 14 days ago

AstraZeneca (AZN) Gains U.S. Approval for Datroway in Breast Cancer Treatment

AstraZeneca, Daiichi Sankyo's Datroway Gets Approval In US For Treatment Of Breast Cancer

2026-05-22T14:54:00.000Z - 14 days ago

AstraZeneca, Daiichi Sankyo's Datroway Gets Approval In US For Treatment Of Breast Cancer

Daiichi Sankyo, AstraZeneca’s Datroway approved in U.S to treat TNBC

2026-05-22T13:54:47.000Z - 14 days ago

Daiichi Sankyo, AstraZeneca’s Datroway approved in U.S to treat TNBC

Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates

May 22, 2026, 9:30 AM EDT - 14 days ago

Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates

AstraZeneca and Daiichi Sankyo’s Enhertu recommended in EU by CHMP in HER2

2026-05-22T12:23:52.000Z - 14 days ago

AstraZeneca and Daiichi Sankyo’s Enhertu recommended in EU by CHMP in HER2

AstraZeneca’s Camizestrant recommended for approval in EU by CHMP

2026-05-22T11:52:49.000Z - 14 days ago

AstraZeneca’s Camizestrant recommended for approval in EU by CHMP

AstraZeneca announces new data from portfolio, pipeline at ASCO meeting

2026-05-22T11:43:07.000Z - 14 days ago

AstraZeneca announces new data from portfolio, pipeline at ASCO meeting

AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026

May 22, 2026, 7:00 AM EDT - 14 days ago

AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026

EU regulator recommends positive opinion of AstraZeneca's experimental breast cancer drug

May 22, 2026, 6:45 AM EDT - 14 days ago

EU regulator recommends positive opinion of AstraZeneca's experimental breast cancer drug

US Supreme Court rebuffs pharma challenge to Biden-era drug price

May 18, 2026, 9:44 AM EDT - 18 days ago

US Supreme Court rebuffs pharma challenge to Biden-era drug price

BMY NVO NVS

BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension

May 18, 2026, 7:00 AM EDT - 18 days ago

BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension

AstraZeneca Gets U.S. Approval for Hypertension Drug

May 18, 2026, 2:13 AM EDT - 18 days ago

AstraZeneca Gets U.S. Approval for Hypertension Drug

AstraZeneca's blood pressure drug wins U.S. approval

May 18, 2026, 2:01 AM EDT - 18 days ago

AstraZeneca's blood pressure drug wins U.S. approval

AstraZeneca's Imfinzi with pre-surgery drug boosts survival in bladder cancer trial

May 14, 2026, 2:59 AM EDT - 22 days ago

AstraZeneca's Imfinzi with pre-surgery drug boosts survival in bladder cancer trial

Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement With AstraZeneca

May 13, 2026, 1:00 AM EDT - 23 days ago

Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement With AstraZeneca

BioInvent to Present Clinical Data on FcγRIIB Antibody BI-1206 Triplet Combination Therapy with rituximab and Calquence(R) in Relapsed/Refractory NHL at EHA 2026

May 12, 2026, 9:45 AM EDT - 24 days ago

BioInvent to Present Clinical Data on FcγRIIB Antibody BI-1206 Triplet Combination Therapy with rituximab and Calquence(R) in Relapsed/Refractory NHL at EHA 2026

R

AstraZeneca stock falls after FDA panel votes against new cancer drug

May 1, 2026, 5:51 AM EDT - 5 weeks ago

AstraZeneca stock falls after FDA panel votes against new cancer drug

AstraZeneca's Breast-Cancer Candidate Drug Loses FDA Panel Vote

May 1, 2026, 3:56 AM EDT - 5 weeks ago

AstraZeneca's Breast-Cancer Candidate Drug Loses FDA Panel Vote

AstraZeneca shares drop after US regulatory panel votes against breast cancer drug

May 1, 2026, 3:09 AM EDT - 5 weeks ago

AstraZeneca shares drop after US regulatory panel votes against breast cancer drug

FDA panel votes against backing AstraZeneca's breast cancer drug

Apr 30, 2026, 1:48 PM EDT - 5 weeks ago

FDA panel votes against backing AstraZeneca's breast cancer drug

Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca

Apr 29, 2026, 7:00 PM EDT - 5 weeks ago

Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca

AstraZeneca Earnings Call Transcript: Q1 2026

Apr 29, 2026, 9:30 AM EDT - 5 weeks ago

AstraZeneca Earnings Call Transcript: Q1 2026

AstraZeneca Quarterly report: Q1 2026

Apr 29, 2026, 9:30 AM EDT - 5 weeks ago

AstraZeneca Quarterly report: Q1 2026

AstraZeneca Slides: Q1 2026

Apr 29, 2026, 9:30 AM EDT - 5 weeks ago

AstraZeneca Slides: Q1 2026

AstraZeneca to make $405 million investment in Britain, PM Starmer says

Apr 29, 2026, 7:26 AM EDT - 5 weeks ago

AstraZeneca to make $405 million investment in Britain, PM Starmer says

AstraZeneca Gets Revenue Boost From Cancer Drugs

Apr 29, 2026, 2:27 AM EDT - 5 weeks ago

AstraZeneca Gets Revenue Boost From Cancer Drugs

AstraZeneca beats profit expectations, keeps annual outlook unchanged

Apr 29, 2026, 2:05 AM EDT - 5 weeks ago

AstraZeneca beats profit expectations, keeps annual outlook unchanged

SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus

Apr 27, 2026, 7:00 AM EDT - 5 weeks ago

SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus

Germany risks missing out on new drugs, AstraZeneca CEO tells paper

Apr 21, 2026, 8:50 AM EDT - 6 weeks ago

Germany risks missing out on new drugs, AstraZeneca CEO tells paper

AstraZeneca's Ultomiris reduces urine protein in late-stage trial of rare kidney disease

Apr 21, 2026, 2:26 AM EDT - 6 weeks ago

AstraZeneca's Ultomiris reduces urine protein in late-stage trial of rare kidney disease

Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD

Apr 20, 2026, 7:00 AM EDT - 6 weeks ago

Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD

AstraZeneca's tozorakimab delivers sharp reduction in COPD flare‑ups

Apr 20, 2026, 2:17 AM EDT - 6 weeks ago

AstraZeneca's tozorakimab delivers sharp reduction in COPD flare‑ups

Trump policies, China's biotech boom are ending Europe's pharma powerhouse era

Apr 11, 2026, 1:54 AM EDT - 7 weeks ago

Trump policies, China's biotech boom are ending Europe's pharma powerhouse era

Swiss industry body says US tariffs on pharmaceuticals will harm patients

Apr 3, 2026, 11:08 AM EDT - 2 months ago

Swiss industry body says US tariffs on pharmaceuticals will harm patients

ABBV AMGN BMY MRK NVO

Trump Administration Unveils Up to 100% Tariff on Branded Drugs

Apr 2, 2026, 5:34 PM EDT - 2 months ago

Trump Administration Unveils Up to 100% Tariff on Branded Drugs

NVO ABBV AMGN BMY MRK

Trump threatens 100% tariff on US drug makers that don't strike deals to lower prices

Apr 2, 2026, 5:33 PM EDT - 2 months ago

Trump threatens 100% tariff on US drug makers that don't strike deals to lower prices

ABBV AMGN BMY MRK NVO

Drugmakers face 100% tariff unless they cut prices or produce drugs in US

Apr 2, 2026, 3:29 PM EDT - 2 months ago

Drugmakers face 100% tariff unless they cut prices or produce drugs in US

NVO ABBV AMGN BMY MRK

Global pharma companies that have publicly announced Trump drug pricing agreements

Apr 2, 2026, 2:59 PM EDT - 2 months ago

Global pharma companies that have publicly announced Trump drug pricing agreements

ABBV AMGN BMY MRK

AstraZeneca's liver cancer therapy combo slows disease progression in late-stage trial

Apr 2, 2026, 6:47 AM EDT - 2 months ago

AstraZeneca's liver cancer therapy combo slows disease progression in late-stage trial

AstraZeneca Confident Rare-Disease Drug Can Hit Target After Mixed Study Results

Mar 31, 2026, 8:23 AM EDT - 2 months ago

AstraZeneca Confident Rare-Disease Drug Can Hit Target After Mixed Study Results

AstraZeneca stock jumps as COPD drug trial win surprises market

Mar 27, 2026, 10:55 AM EDT - 2 months ago

AstraZeneca stock jumps as COPD drug trial win surprises market

AstraZeneca stock jumps 4% after surprise trial win for lung disease drug where rivals have failed

Mar 27, 2026, 8:54 AM EDT - 2 months ago

AstraZeneca stock jumps 4% after surprise trial win for lung disease drug where rivals have failed

Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD

Mar 27, 2026, 7:00 AM EDT - 2 months ago

Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD

AstraZeneca Lung Disease Drug Candidate Hits Goals in Late-Stage Trials

Mar 27, 2026, 3:51 AM EDT - 2 months ago

AstraZeneca Lung Disease Drug Candidate Hits Goals in Late-Stage Trials

AstraZeneca drug reduces COPD flare ups in late-stage trials

Mar 27, 2026, 3:18 AM EDT - 2 months ago

AstraZeneca drug reduces COPD flare ups in late-stage trials

AstraZeneca says it will build cell therapy base, innovation centre in Shanghai

Mar 19, 2026, 12:52 AM EDT - 2 months ago

AstraZeneca says it will build cell therapy base, innovation centre in Shanghai

TrumpRx lists many medicines at prices higher than paid in UK

Mar 18, 2026, 2:23 PM EDT - 2 months ago

TrumpRx lists many medicines at prices higher than paid in UK

ABBV AMGN BMY GILD GSK JNJ LLY

Big drugmakers must face US overcharge claims on medications for low-income patients

Mar 17, 2026, 2:32 PM EDT - 2 months ago

Big drugmakers must face US overcharge claims on medications for low-income patients

ABBV NVS SNY

AstraZeneca's Imfinzi Gets EU Approval for Treatment of Early Gastric Cancer

Mar 16, 2026, 2:58 AM EDT - 2 months ago

AstraZeneca's Imfinzi Gets EU Approval for Treatment of Early Gastric Cancer

Health Rounds: Death from dementia on the rise among people with type 2 diabetes

Mar 11, 2026, 7:28 AM EDT - 3 months ago

Health Rounds: Death from dementia on the rise among people with type 2 diabetes

LLY NVO

AstraZeneca and Joshua Jackson partner to encourage fans to Get Body Checked Against Cancer

Mar 10, 2026, 8:30 AM EDT - 3 months ago

AstraZeneca and Joshua Jackson partner to encourage fans to Get Body Checked Against Cancer

truehealthvalue
truehealthvalue Jun. 5 at 9:27 AM
$AZN I would look at $ELTX, About to take off, it will be worth billions in a short time
0 · Reply
P0rNsTaR
P0rNsTaR Jun. 3 at 7:07 PM
$ABVX with MC at under $6B, there's a almost 300% upside here. $LLY $AZN
0 · Reply
monstertrades1
monstertrades1 Jun. 3 at 7:02 PM
$AREC $AZN $BMEA $MTVA $WMT
0 · Reply
G101SPM
G101SPM Jun. 3 at 6:52 PM
#SHOWTIME American Diabetes Association Scientific Conference (June 4-8) Scheduled to appear: $AREC, $AZN, $BMEA, $MTVA, IPSC... Walmart Inc. Annual General Meeting (June 4) Scheduled to appear: $WMT
0 · Reply
Chipwars
Chipwars Jun. 3 at 5:23 PM
$AZN Only 16x PE. Good entry point here, IMO. Astrazeneca. https://finance.yahoo.com/sectors/healthcare/articles/astrazenecas-expanding-cancer-portfolio-sustain-140900834.html
0 · Reply
Chipwars
Chipwars Jun. 3 at 10:52 AM
$AZN Astrazeneca. Deutsche Bank are crooked short sellers. They've done this before. The stock will come back as they are proved wrong. Again.
0 · Reply
Chipwars
Chipwars Jun. 3 at 10:25 AM
$AZN https://www.fiercepharma.com/pharma/asco-astrazenecas-imfinzi-imjudo-duo-shines-earlier-stage-liver-cancer-win
0 · Reply
GreenEnergy7B
GreenEnergy7B Jun. 3 at 9:33 AM
$ALT "Weight-loss drugs can cut breast cancer risk by up to 30%, studies suggest" "The first study, a retrospective analysis of 110,000 women aged between 45 and 80, found those who took GLP-1 medications were 30% less likely to develop breast cancer than those who did not." https://www.theguardian.com/science/2026/jun/02/weight-loss-drugs-cut-cancer-risk-studies $NVO $PFE $AZN $SNY
0 · Reply
DeadInvestor
DeadInvestor Jun. 2 at 6:23 PM
$TVTX BofA raised their target to $59 from $50 on May 28, following the patent extension news. H.C. Wainwright raised its price target on the stock to $67 from $57 $AZN $NVS better buy TVTX fast, as The price will continue to climb, ratcheting up the buyout price for acquirer.
0 · Reply
Chipwars
Chipwars Jun. 2 at 2:08 PM
$AZN Astrazeneca gives hope to thousands of people : https://www.stocktitan.net/news/AZN/camizestrant-combination-delayed-time-to-first-progression-by-55-and-3aod76a3qnbk.html
0 · Reply
Chipwars
Chipwars Jun. 2 at 8:06 AM
$AZN AstraZeneca announced several positive developments on the same day. These included encouraging results from the EMERALD-3 Phase III trial for a liver cancer treatment, an FDA approval for an Imfinzi-BCG combination for high-risk bladder cancer, and positive initial data for AZD-3470 in classical Hodgkin lymphoma.
0 · Reply
Chipwars
Chipwars Jun. 2 at 8:00 AM
$AZN https://www.marketscreener.com/news/astrazeneca-buy-rating-from-jp-morgan-ce7f5dd8df81f124
0 · Reply
Chipwars
Chipwars Jun. 2 at 7:57 AM
$AZN Astrazeneca going to £16500 $AZN https://www.marketscreener.com/news/astrazeneca-barclays-gives-a-buy-rating-ce7f5dd9d880fe27
0 · Reply
Chipwars
Chipwars Jun. 2 at 7:53 AM
$AZN Astrazeneca, more good news. https://www.investors.com/news/technology/astrazeneca-imfinzi-liver-cancer-treatment/
0 · Reply
zerodayrounder
zerodayrounder Jun. 1 at 5:34 PM
$CGEN pretty nasty price action here. I'm not following closely -- what is chances one of their Big Pharma partners takes them out? Doesn't $AZN have like 12 programs dependent on molecules licensed from CGEN?
0 · Reply
SaySomethingNice
SaySomethingNice Jun. 1 at 2:21 PM
$AIM $AZN $VXF
0 · Reply
StocktwitsNews
StocktwitsNews Jun. 1 at 2:19 PM
AIM Stock Soars 42% As Pancreatic Cancer Trial Hits Key Enrollment Milestone Before Schedule — CEO Sees 'Significant Value-Inflection Period' Ahead $AIM $AZN $VXF https://stocktwits.com/news/equity/markets/why-is-aim-stock-soaring-today-pancreatic-cancer-trial-enrollment/cZ0guolReHs
0 · Reply
clan
clan Jun. 1 at 12:36 PM
$AZN ⚠️ Great news for diabetic kiddos ! ! ! 👍👍 FDA APPROVED - - - AFREZZA For the good of all MannKind! T1Ds and Type 2s are NOW ready for the future! Inhalable mealtime insulin! Wow! 😲😃 🚫💉 No needles! $CPIX $PLRX $GRI
0 · Reply
TangibleOne
TangibleOne Jun. 1 at 8:50 AM
$AZN this and SKM (ticker) for the Anthropic pre IPO exposure 😏🙏
0 · Reply
maikl_211
maikl_211 Jun. 1 at 4:55 AM
$AZN $MS $GS $SAP $HSBC
0 · Reply
Eagley3k
Eagley3k May. 31 at 12:46 AM
$PFE $AZN $AMGN hope everyone makes a killing here. Bring your money to $OSTX on monday for tuesday monrning news.
0 · Reply
DeadInvestor
DeadInvestor May. 29 at 4:09 PM
$AZN $NVS $TVTX Acquisition Candidates — Who Buys TVTX? This is where it gets genuinely interesting. TVTX has a profile that is almost tailor-made for acquisition: First-in-class rare kidney disease franchise Two approved indications with clear growth runway Patent protection to 2037 Manageable size (~$4.3B market cap) for large pharma Rare disease commercial infrastructure already built Most Likely Acquirers 1. AstraZeneca — Highest probability AZ has aggressively built a rare kidney/nephrology franchise (Farxiga, Lokelma) and has explicitly stated renal disease as a strategic priority. FILSPARI would slot directly into their existing nephrology commercial infrastructure and physician relationships, creating enormous synergies. 2. Novartis — Very strong candidate Novartis has deep rare disease expertise (Cosentyx, Kesimpta) and has been acquisitive in the space. Their existing rare disease infrastructure and global reach would dramatically accelerate FILSPARI's international expansion, partic…
0 · Reply